Delivery Order SPE2DB22D3009-SPE2DB25FBD40
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $3,877.08 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen medications on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order valued at $14,430.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injections. This is a firm fixed price, competitively awarded delivery order with a completion date of July 22, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in Conshohocken, PA 19428....
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $22,077.35 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $1,709.46 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $9,481.08 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $5,128.38. This firm fixed-price, non-set-aside contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $11,468.93 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a completion date of August 12, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The vendor will perform this work from its corporate office in Conshohocken, Pennsylvania, where...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD40Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $30,929.96 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical supply will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and distribution hub for federal medical procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, fulfills a critical role in the federal medical supply chain, particularly supporting military and veteran healthcare systems. The company's extensive portfolio of delivery orders through the DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products, vaccines, and medical devices across multiple therapeutic domains. This contract for Dupixent, a specialty biologic medication, exemplifies the company's role in delivering specialized healthcare commodities to support Defense Health Agency operations and other federal health programs on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.9k | 8/18/25 |